Focusing on ophthalmic diseases with its portfolio of small-molecule nerve growth factor (NGF) mimetic compounds, Mimetogen Pharmaceuticals Inc. is capitalizing on a large, relatively underserved medical market that is growing at about twice the rate of the general pharmaceutical sector: ophthalmology.
Lupus took the spotlight twice in November, first when Resolve Therapeutics LLC entered this active area of drug development and licensed compounds and technology targeting the interferon-alfa pathway from the University of Washington School of Medicine in Seattle.
NEW YORK – In spite of having the world's highest number of life science patents per capita, a highly developed academic research infrastructure, and entrepreneurial know-how, Israel still has trouble commercializing its discoveries due to a number of factors, mostly financing. But the Israeli biotech industry is finally coming of age, according to 14 company presentations at this week's Tel Aviv Stock Exchange (TASE)-NASDAQ Biomed Conference held at NASDAQ's New York headquarters.
